Efficacy of pegylated interferon α-2b plus entecavir therapy and predictors of treatment success in children with chronic hepatitis B
IntroductionInterferon therapy, used in the treatment of chronic hepatitis B (CHB), is one of the means by which patients can achieve a functional cure. Pegylated interferon is currently used in the treatment of CHB. There are two main types of pegylated interferon: α-2b and α-2a.MethodsThis study e...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-12-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1282922/full |
| _version_ | 1797405164359909376 |
|---|---|
| author | Liang Huang Hong Zhang Xintong Kang Zhu Chen Lin Wang Yilan Zeng |
| author_facet | Liang Huang Hong Zhang Xintong Kang Zhu Chen Lin Wang Yilan Zeng |
| author_sort | Liang Huang |
| collection | DOAJ |
| description | IntroductionInterferon therapy, used in the treatment of chronic hepatitis B (CHB), is one of the means by which patients can achieve a functional cure. Pegylated interferon is currently used in the treatment of CHB. There are two main types of pegylated interferon: α-2b and α-2a.MethodsThis study explored the efficacy, safety, and predictors of treatment response for α-2b plus entecavir among children in a real-world setting.ResultsThe study included 76 patients aged 3–18 years, all of whom were treated with interferon α-2b plus entecavir. The mean duration of treatment was 401.99 days, and 31.6% (24/76) of patients achieved HBsAg clearance. Competing risk model analyses showed that children with baseline HBsAg <1500 IU/mL (subdistribution hazard ratio [sHR]=2.643, P=0.022) and a higher baseline alanine aminotransferase (ALT) level (sHR=1.005, P=0.000) had a higher probability of achieving HBsAg clearance during treatment. Conversely, children with a higher hepatitis B virus loading level (sHR=0.835, P=0.043) and age ≥10 years (sHR=0.243, P=0.002) had a lower probability of achieving HBsAg clearance during treatment. A decrease of >1 log10 in HBsAg level (sHR=3.479, P=0.001) at 12 weeks of treatment was associated with a higher probability of achieving surface antigen clearance.DiscussionThese results indicated that interferon plus entecavir therapy is a promising means of achieving HBsAg clearance in children with CHB. Moreover, HBsAg, ALT, virus loading, and age are indicators of treatment success probability. |
| first_indexed | 2024-03-09T03:06:50Z |
| format | Article |
| id | doaj.art-379eb6289a8f4e4c8c9aaa200542cd3f |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-09T03:06:50Z |
| publishDate | 2023-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-379eb6289a8f4e4c8c9aaa200542cd3f2023-12-04T06:50:40ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-12-011410.3389/fimmu.2023.12829221282922Efficacy of pegylated interferon α-2b plus entecavir therapy and predictors of treatment success in children with chronic hepatitis BLiang HuangHong ZhangXintong KangZhu ChenLin WangYilan ZengIntroductionInterferon therapy, used in the treatment of chronic hepatitis B (CHB), is one of the means by which patients can achieve a functional cure. Pegylated interferon is currently used in the treatment of CHB. There are two main types of pegylated interferon: α-2b and α-2a.MethodsThis study explored the efficacy, safety, and predictors of treatment response for α-2b plus entecavir among children in a real-world setting.ResultsThe study included 76 patients aged 3–18 years, all of whom were treated with interferon α-2b plus entecavir. The mean duration of treatment was 401.99 days, and 31.6% (24/76) of patients achieved HBsAg clearance. Competing risk model analyses showed that children with baseline HBsAg <1500 IU/mL (subdistribution hazard ratio [sHR]=2.643, P=0.022) and a higher baseline alanine aminotransferase (ALT) level (sHR=1.005, P=0.000) had a higher probability of achieving HBsAg clearance during treatment. Conversely, children with a higher hepatitis B virus loading level (sHR=0.835, P=0.043) and age ≥10 years (sHR=0.243, P=0.002) had a lower probability of achieving HBsAg clearance during treatment. A decrease of >1 log10 in HBsAg level (sHR=3.479, P=0.001) at 12 weeks of treatment was associated with a higher probability of achieving surface antigen clearance.DiscussionThese results indicated that interferon plus entecavir therapy is a promising means of achieving HBsAg clearance in children with CHB. Moreover, HBsAg, ALT, virus loading, and age are indicators of treatment success probability.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1282922/fullpegylated interferon α-2bentecavirefficacychronic hepatitis Bpredictors |
| spellingShingle | Liang Huang Hong Zhang Xintong Kang Zhu Chen Lin Wang Yilan Zeng Efficacy of pegylated interferon α-2b plus entecavir therapy and predictors of treatment success in children with chronic hepatitis B Frontiers in Immunology pegylated interferon α-2b entecavir efficacy chronic hepatitis B predictors |
| title | Efficacy of pegylated interferon α-2b plus entecavir therapy and predictors of treatment success in children with chronic hepatitis B |
| title_full | Efficacy of pegylated interferon α-2b plus entecavir therapy and predictors of treatment success in children with chronic hepatitis B |
| title_fullStr | Efficacy of pegylated interferon α-2b plus entecavir therapy and predictors of treatment success in children with chronic hepatitis B |
| title_full_unstemmed | Efficacy of pegylated interferon α-2b plus entecavir therapy and predictors of treatment success in children with chronic hepatitis B |
| title_short | Efficacy of pegylated interferon α-2b plus entecavir therapy and predictors of treatment success in children with chronic hepatitis B |
| title_sort | efficacy of pegylated interferon α 2b plus entecavir therapy and predictors of treatment success in children with chronic hepatitis b |
| topic | pegylated interferon α-2b entecavir efficacy chronic hepatitis B predictors |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1282922/full |
| work_keys_str_mv | AT lianghuang efficacyofpegylatedinterferona2bplusentecavirtherapyandpredictorsoftreatmentsuccessinchildrenwithchronichepatitisb AT hongzhang efficacyofpegylatedinterferona2bplusentecavirtherapyandpredictorsoftreatmentsuccessinchildrenwithchronichepatitisb AT xintongkang efficacyofpegylatedinterferona2bplusentecavirtherapyandpredictorsoftreatmentsuccessinchildrenwithchronichepatitisb AT zhuchen efficacyofpegylatedinterferona2bplusentecavirtherapyandpredictorsoftreatmentsuccessinchildrenwithchronichepatitisb AT linwang efficacyofpegylatedinterferona2bplusentecavirtherapyandpredictorsoftreatmentsuccessinchildrenwithchronichepatitisb AT yilanzeng efficacyofpegylatedinterferona2bplusentecavirtherapyandpredictorsoftreatmentsuccessinchildrenwithchronichepatitisb |